Onyx Scientific Limited Boosts U.S. Commercial Team

Onyx Scientific Limited Boosts U.S. Commercial Team

February 2013 -- CHEMISTRY specialist Onyx Scientific has further strengthened its US team with the appointment of another business development professional.
Adam Moorhouse joins the contract research and manufacturing organisation as a Director of Business Development and will be responsible for developing new prospects for the UK-based company is Western USA.

30-year-old Adam is the latest high-profile appointment for Onyx Scientific after the company recruited Chicago-based commercial executive Dan Brisard to oversee its business development activities across the eastern half of the US in November.

With a first class degree in Chemistry from the University of Oxford and a PhD in Organic Medicinal Chemistry from the University of Nottingham, Adam brings impressive technical knowledge to his new role.

Vineet Luhariwala, business unit head at Onyx Scientific, said: "Adam demonstrates a very high level of energy and enthusiasm that will no doubt make him a major asset to our business development team.

"His superb chemistry knowledge will equip him well to identify and pursue business opportunities with existing pharmaceutical and biotechnology clients and prospects on the West Coast."

With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.

Adam joins the CRO following two years working in international business development and account management for a UK-based laboratory instrument manufacturer.

He said: "Given my qualifications in chemistry and recent commercial experience, joining a well-established company like Onyx Scientific is a great opportunity. The backing and strategic alliance of a large, successful Indian company like Ipca Laboratories also proved a very attractive proposition.

"Upon meeting the friendly staff and seeing the UK premises, I discovered a highly professional, intelligent and experienced outfit accompanied by state of the art facilities that further bolstered my enthusiasm.

"I am looking forward to representing Onyx Scientific in the US, with the confidence in the knowledge that the contract service we provide is strong enough to generate 96% customer return business."

Onyx Scientific's UK-based labs deal with complex chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its commercial manufacturing sites in India.

For more information about Onyx Scientific – visit www.onyxipca.com and follow on Twitter and LinkedIn

For further information, images and interview opportunities, please contact Raman Sehgal [email protected] | 07808796300 | www.ramarketingpr.com | www.twitter.com/ramarketingpr

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.